High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab

Publisher： Karger

E-ISSN： 1421-9662|126|1|44-51

ISSN： 0001-5792

Source： Acta Haematologica, Vol.126, Iss.1, 2011-03, pp. : 44-51

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B‐cell lymphoma in the rituximab era

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 776-783

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Prognostic Impact of Absolute Lymphocyte and Monocyte Counts at Diagnosis of Diffuse Large B-Cell Lymphoma in the Rituximab Era

By  

Acta Haematologica, Vol. 130, Iss. 4, 2013-07 ,pp. : 242-246

Karger

Access to resources Recommend Favorite

Dose-Dense CHOP plus Rituximab (R-CHOP14) for the Treatment of Elderly Patients with High-Risk Diffuse Large B Cell Lymphoma: A Pilot Study

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 22-27

Karger

Access to resources Recommend Favorite

Diffuse Large Cell Lymphomas: Identification of Prognostic Factors and Validation of the International Non-Hodgkin’s Lymphoma Prognostic Index

By  

Oncology, Vol. 55, Iss. 5, 1998-08 ,pp. : 405-415

Karger

Access to resources Recommend Favorite

Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy

By  

Acta Haematologica, Vol. 137, Iss. 2, 2017-01 ,pp. : 76-85

Karger

Access to resources Recommend Favorite